TOGGLE MENU TOGGLE SEARCH Investors In this section: SEC FILINGS NEWSROOM CORPORATE GOVERNANCE STOCK INFORMATION CORPORATE PRESENTATION MEDIA RESOURCES EVENTS AGM Freeline is a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases. Making gene therapy a reality Since the foundation of Freeline in 2015, the aim has been to advance curative gene therapy treatments for chronic systemic diseases which have not to date been treatable. An entrepreneurial spirit and a vision to challenge the standard of care to create better lives has been the driving force behind Freeline. We are using our novel platform technology across our pipeline of indications, with early investment in GMP compliance alongside in-house manufacturing to expedite our path to drug development. STOCK INFORMATION PRICE $2.28 CHANGE -$0.01 Dec 2, 2021 4:00 PM ET (Pricing delayed by 20 minutes) MORE STOCK INFORMATION LATEST NEWS Freeline to Participate in Evercore ISI 4th Annual HealthCONx Conference 23 November 2021 LONDON, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, today READ FULL STORY Freeline to Participate in Stifel 2021 Virtual Healthcare Conference 10 November 2021 LONDON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, today READ FULL STORY Freeline Reports New Data from Fabry Disease Program, Pipeline and Company Updates, Including Appointment of Pamela Foulds, MD as Chief Medical Officer, and Third Quarter 2021 Financial Results 09 November 2021 Freeline today announced new data from its ongoing Phase 1/2 MARVEL-1 dose-finding clinical trial of FLT190 for the treatment of Fabry disease and provided updates on its pipeline programs. The Company also announced that Pamela Foulds, MD has been appointed as Chief Medical Officer (CMO) and reported financial results for the third quarter of 2021. READ FULL STORY Sign up for news and alerts SIGN UP NOW PRESENTATIONS Freeline Corporate Presentation November 2021 09 November 2021 Freeline Corporate Presentation November 2021 FREELINE CORPORATE PRESENTATION NOVEMBER 2021 (6.07MB) Development of a 96-Well Plate-Based High-Throughput System for rAAV Manufacturing Platform Optimization and Candidate Selection 11 May 2021 VIEW PRESENTATION VIDEO PUBLICATIONS Evaluation of life cycle defective adenovirus mutants for production of adeno‐associated virus vectors The Journal of Gene Medicine 30 April 2019 The study indicates the advantages of using a ∆pTP mutant adenovirus rather than adenovirus wild‐type as a helper virus for AAV2 production and also indicates that temperature shifts to lower temperatures may improve AAV2 vector production rates. READ PUBLICATION Liver-directed gene therapy corrects Fabry disease in mice Elsevier 04 February 2019 We examined the therapeutic efficacy of GLA gene therapy in Fabry mice using recombinant adeno-associated virus (rAAV) vectors, directed by the liver-specific promoter (FRE1). The data resulting from this study provides strong evidence that our liver-directed AAV-mediated gene therapy approach holds considerable therapeutic potential for the treatment of Fabry disease. READ PUBLICATION Liver directed AAV gene therapy to treat Gaucher disease Elsevier 04 February 2019 We used an adeno-associated viral vector (AAV) to drive the expression of human GBA gene in the liver of mice and observed noticeable uptake of human GCase in affected organs. Overall, the data showed that upon a single injection of a liver-expression-directed AAV vector it is possible to achieve elevation of GCase in the bloodstream that results in greater GCase bioavailability compared to current ERT. READ PUBLICATION Investor relations investor@freeline.life T: +44 (0)1438 906870 Get in touch T. Telephone: +44 (0)1438 906870 E. Email: contact@freeline.life Follow us on our social channels About us Innovation Patients & families Healthcare professionals Careers Investors Contact Terms of use Privacy Notice Accessibility Cookie Policy ©2021 Freeline